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In the present study, we show that human FKHRL1 is a direct target of Akt phosphorylation and that Akt phosphorylation of FKHRL1 results in FKHRL1 retention in the cytoplasm and the inhibition of FKHRL1-dependent transcription. Survival factor withdrawal induces FKHRL1 dephosphorylation and translocation to the nucleus. Within the nucleus, the dephosphorylated FKHRL1 induces target genes such as Fas ligand and triggers apoptosis. We propose that growth factors, by triggering the Akt-dependent phosphorylation and inactivation of FKHRL1 function, suppress the transcription of death genes, such as the Fas ligand gene, and thereby promote cell survival.
Results

Akt Phosphorylates FKHRL1 In Vitro
We initially tested the FKHRL1 isoform as an Akt substrate, since Northern blot experiments had shown that the FKHRL1 mRNA is the most ubiquitously expressed of the three mammalian DAF16 homologs (Anderson et al., 1998) . To determine whether FKHRL1 is a substrate of Akt in vitro, we produced in bacteria a GST-FKHRL1 fusion protein and a series of mutants in which one or three of the putative Akt phosphorylation sites (T32, mutants of FKHRL1 in which just one of these sites was converted to an alanine ( Figure 1A ). Whereas the S315A phosphorylated at T32 and demonstrate that Akt phosmutant was phosphorylated to the same extent as the phorylates FKHRL1 at T32 in vitro. By a similar strategy, wild-type FKHRL1 protein, the T32A and the S253A muwe demonstrated that the anti-phospho S253 antibody tants were phosphorylated at a significantly lower level, is specific to FKHRL1 that is phosphorylated at S253 indicating that T32 and S253 of FKHRL1 are likely to be and that Akt phosphorylates FKHRL1 at S253 in vitro Akt targets. However, both the T32A and S253A mutants ( Figure 1B , middle panel). displayed residual phosphorylation by Akt ( Figure 1A) , suggesting that when one of these sites is mutated, the Akt Phosphorylates FKHRL1 In Vivo other site is still phosphorylated. By contrast, a FKHRL1
To determine whether Akt phosphorylates FKHRL1 at protein in which all three of the putative Akt phosphory-T32, S253, and/or S315 within cells, we generated HA lation sites were converted to alanines was no longer epitope-tagged versions of wild-type and phosphoryladetectably phosphorylated by Akt ( Figure 1A) , indicating tion mutants of FKHRL1. These constructs were transthat there are no other sites within FKHRL1 that are fected into 293T cells and the expression of FKHRL1 significantly phosphorylated by Akt in vitro. monitored by immunoblotting with an anti-FKHRL1 antiTo confirm that T32 and S253 are the sites of Aktbody ( Figure 2A, bottom panel) . The phosphorylation of catalyzed phosphorylation in vitro, we raised antibodies FKHRL1 at T32 or S253 was monitored by immunoblotto phosphopeptides that correspond to these two phosting with anti-phospho FKHRL1-specific antibodies (Figphorylation sites and used the antibodies in immuure 2A, top and middle panels). When 293T cells were noblotting experiments ( Figure 1B) . The anti-phospho grown in the presence of growth factors, the anti-phos-T32 peptide antibody recognized wt FKHRL1 that was pho T32 and anti-phospho S253 antibodies recognized incubated with a constitutively active form of Akt in an wild-type FKHRL1 but not the corresponding single muin vitro kinase assay but failed to recognize unphosphortants (T32A and S235A, respectively), the corresponding ylated FKHRL1 ( Figure 1B, top panel) . Moreover, the double mutants, or the triple mutant of FKHRL1 (Figure anti-phospho T32 antibody did not recognize FKHRL1 2A). These findings confirm the specificity of the antiin which T32 had been converted to an alanine, but it phospho T32 and anti-phospho S253 antibodies and was able to effectively recognize FKHRL1 in which S253
indicate that in the presence of growth factors, condior S315 was converted to an alanine ( Figure 1B, top tions under which the PI3K/Akt pathway is active, panel). These findings indicate that the anti-phospho FKHRL1 is phosphorylated within cells at both T32 and S253. T32 antibody specifically recognizes FKHRL1 when it is 
To determine whether FKHRL1 phosphorylation is in-
The anti-phosphoantibodies that we generated to the phosphopeptide that spans S315 were found not to be duced by the addition of survival factors, we expressed HA-tagged FKHRL1 in the IGF1-responsive fibroblast site specific (data not shown). To assay Akt's ability to catalyze the phosphorylation of FKHRL1 at S315, we cell line CCL39 and examined the phosphorylation status of FKHRL1 using the phosphoantibodies in immutook advantage of the finding that the presence of IGF1 or the expression of a constitutively active Akt induced noblot experiments. We found that a 20 min exposure of fibroblasts to IGF1 induced the phosphorylation of a shift up in the mobility of wt FKHRL1 on an SDS gel ( Figure 2C ). When FKHRL1 S315 was mutated to an FKHRL1 at T32 and S253 ( Figure 2B ). To determine whether IGF1 induction of FKHRL1 phosphorylation was alanine, Akt no longer induced a shift in FKHRL1 mobility ( Figure 2C ). By contrast, mutating FKHRL1 T32 and S253 mediated by the PI3K pathway, we examined the effect of an inhibitor of PI3K, LY 294002 (LY), on FKHRL1 phosto alanines had no effect on Akt's ability to induce a shift in FKHRL1 mobility ( Figure 2C ). These findings indiphorylation. The phosphorylation of both T32 and S253 was inhibited by LY treatment (Figure 2B) to alanines was exclusively nuclear (Figures 3A and 3B ). This indicates that phosphorylation at these three sites alters the subcellular distribution of FKHRL1. When not To this end, we coexpressed FKHRL1 and the zeta isophosphorylated, FKHRL1 is localized to the nucleus. By form of 14-3-3 in 293T cells in the presence of growth contrast, when these three sites are phosphorylated, factors. Immunoprecipitation experiments followed by FKHRL1 is retained in the cytoplasm.
immunoblotting showed that wild-type FKHRL1 interDetailed comparison of each of the FKHRL1 phosacts with 14-3-3 zeta (Figure 4 ). To determine whether phorylation mutants revealed that when either T32, the phosphorylation of FKHRL1 was critical for this inter-S253, or S315 was mutated to an alanine, the number action, we tested the mutants of the FKHRL1 phosphorof cells expressing FKHRL1 in the nucleus was substanylation sites in the coimmunoprecipitation assay (Figure tially increased (data not shown). An analysis of the 4). The S315A mutant of FKHRL1 interacted with 14-3-3 subcellular localization of the double mutants revealed to the same extent as wild-type FKHRL1, indicating that that the mutation of two of the phosphorylation sites the phosphorylation of S315 is not required for 14-3-3 resulted in an even greater percentage of cells showing binding. By contrast, both T32A and S253A single mu-FKHRL1 within their nucleus (data not shown), sugtants of FKHRL1 interacted less efficiently than wildgesting that phosphorylation of FKHRL1 at all three sites type FKHRL1 with 14-3-3. Moreover, the interaction of is necessary to retain FKHRL1 completely within the FKHRL1 with 14-3-3 was abolished when T32 and S253 cytoplasm.
of FKHRL1 were both converted to alanines, indicating Taken together, these findings indicate that growth that phosphorylation of both sites contributes to 14-3-3 factor stimulation via the endogenous PI3K/Akt pathway binding. These findings suggest that Akt may proinduces the phosphorylation of FKHRL1 at three sites mote FKHRL1's interaction with 14-3-3 by phosphorylatthat play an important role in sequestering FKHRL1 in ing FKHRL1 at T32 and S253. Thus, in growth factorthe cytoplasm, away from FKHRL1's target genes in the stimulated cells, a function of 14-3-3 may be to bind the nucleus. phosphorylated form of FKHRL1 and thereby sequester FKHRL1 in the cytoplasm so that it is unable to regulate its target genes in the nucleus. Phosphorylated FKHRL1 Binds to 14-3-3 We next considered the possibility that the phosphorylation of FKHRL1 might cause FKHRL1 sequestration in Identification of DNA-Binding Sites for FKHRL1 the cytoplasm by promoting FKHRL1's interaction with a To address FKHRL1's mechanism of action within the protein that functions as a scaffold within the cytoplasm. nucleus, we first examined the ability of FKHRL1 to interOne group of scaffolding proteins that specifically bind act with specific DNA sequences using a DNA mobility certain phospho-serine-containing proteins is the 14-shift assay. Although FKHRL1 contains a "Forkhead do-3-3 family of proteins. Given that the amino acid semain" that has been shown to be a DNA-binding domain quence surrounding T32 is a perfect consensus site for for all FH family members, it had not been determined 14-3-3 binding, except for the substitution of a Thr for whether FKHRL1 or DAF16 interacts directly with DNA. a Ser (Yaffe et al., 1997) , we investigated whether the Moreover, the sequence of DNA recognized by FKHRL1 remained to be identified. T32 phosphorylated form of FKHRL1 binds to 14-3-3. to the Promega protocol. ␤-galactosidase activity was assayed as P-S253: CKAPRRRAVpSMDNS; P-S315: CTDFRSRTNpSNAST) and described (Maniatis et al., 1989). coupled to KLH (Pierce). Antibodies to the KLH-coupled peptides and purified full-length GST-FKHRL1 were obtained and purified as Survival Assays previously described (Datta et al., 1997) .
Cerebellar granule neurons were seeded onto glass coverslips in 24-well plates at a density of 10 7 cells/well and at DIV5-6 were Cell Culture cotransfected with 2 g of the construct of interest, 1 g of the The 293T human epithelial kidney cell line and the Chinese hamster CMV-GFP plasmid, and 0.5 g of the CMV-LacZ plasmid as delung fibroblast cell line CCL39 (ATCC) were cultured in DMEM supscribed (Dudek et al., 1997). Twenty-four hours after transfection, plemented with 10% FCS (GIBCO) and antibiotics (50 U/ml penicillin cells were incubated for 20 hr in the presence of IGF1 and incubated and 50 g/ml streptomycin). Jurkat T lymphocytes were cultured or not with Fas-Fc or Fc alone (1 g/ml). The transfected neurons in RPMI supplemented with 10% FCS and antibiotics. Cerebellar were then fixed in 4% paraformaldehyde/2% sucrose. Immunofluogranule cells were obtained from P6 Long Evans rats and cultured rescence analyses were performed as described above using the as previously described (Dudek et al., 1997) . Unless otherwise anti-␤-galactosidase antibody (Pharmacia), and nuclei were stained stated, cells were transfected by the calcium phosphate technique.
by Hoechst 33258 (2.5 g/ml). Apoptotic nuclei were counted in a blinded manner. CCL39 fibroblats were transfected with 4 g of the relevant plasKinase Assays 293T cells were seeded in 35 mm dishes at the density of 750,000 mid and 1 g of the plasmid encoding GFP. They were treated in the same way as described for neurons, and apoptotic nuclei of cells per dish. They were transfected with 5 g of the HA-Akt expression vectors. Twenty-four hours after transfection, cells were starved GFP-positive cells were counted in a blinded manner. Jurkat cells were transfected by electroporation (250 V, 950 F, in serum-free medium for 20 hr. Extracts were obtained and kinase assays were performed as described (Dudek et al., 1997) using 5 Biorad) with 16 g of the relevant plasmids and 4 g of the plasmid encoding GFP. GFP-positive cells were scored for apoptosis as g of purified GST protein as a substrate and 5 Ci, 50 M of ␥ 32 P ATP for 1 hr at 30ЊC. The reaction products were resolved by described above.
